Clinical Trial Update: Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a regimen of obinutuzumab, zanubrutinib, and lenalidomide, followed by a short cycle of obinutuzumab and cytarabine, in newly diagnosed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Brukinsa (zanubrutinib) (zanubrutinib)
• CYTARABINE (CYTARABINE)
• Gazyva (obinutuzumab) (obinutuzumab)
• Revlimid (lenalidomide) (lenalidomide)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: RECRUITING